Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Core Viewpoint - AbbVie Inc. has filed a lawsuit against Genmab A/S and others, alleging misappropriation of trade secrets related to disaccharides used in antibody-drug conjugates (ADCs) [1][2][3] Group 1: Legal Proceedings - AbbVie is seeking damages and broad injunctive reliefs, claiming that Genmab and others have misappropriated its trade secrets [2] - Genmab categorically refutes the allegations and intends to vigorously defend against AbbVie's claims [2][3] - This lawsuit is part of a series of recent legal actions by AbbVie against competitors for similar allegations [3] Group 2: Product Information - The complaint pertains to Rina-S™, a clinical-stage ADC targeting FRα, currently in Phase 3 development for ovarian cancer and other solid tumors [4] - Rina-S™ utilizes a proprietary antibody and a unique linker to achieve a drug-to-antibody ratio (DAR) of 8 for the payload, exatecan [4] - Genmab aims to broaden the development plans for Rina-S™ based on ongoing clinical trial data, potentially addressing a wider patient population in ovarian cancer [5] Group 3: Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody-based medicines [6][9] - The company has a strong track record in the discovery and commercialization of differentiated antibody therapeutics [6] - Genmab's vision by 2030 is to transform the lives of patients with cancer through advanced antibody medicines [9]